MedTrace Logo

Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients

NCT04076228 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2020-09-02

No results posted yet for this study

Summary

Pembrolizumab is approved for advanced stage non-small cell lung cancer. However, the response rate is low (around 10-15 %) in patients treated in Macau SAR, China. The investigators hypothesize CD38 expressing cells and/or other immune populations will help to predict response.

Conditions

  • NSCLC Stage IV

Interventions

DRUG

Pembrolizumab

pembrolizumab is a PD-1 inhibitor. Treatment and follow up will be performed at Kiang Wu Hospital in their clinical oncology center. Clinically pathological related information will be recorded.

Sponsors & Collaborators

  • Kiang Wu Hospital

    lead OTHER

Principal Investigators

  • Yabing Cao, MD; PhD · Kiang Wu Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2020-01-01
Completion
2020-01-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04076228 on ClinicalTrials.gov